The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis by Peng, Zhen‐Wei et al.
The ectonucleotidase ENTPD1/CD39
limits biliary injury and fibrosis in
mouse models of sclerosing cholangitis
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Peng, Z., S. Rothweiler, G. Wei, N. Ikenaga, S. B. Liu, D. Y. Sverdlov,
K. A. Vaid, et al. 2017. “The ectonucleotidase ENTPD1/CD39
limits biliary injury and fibrosis in mouse models of sclerosing
cholangitis.” Hepatology Communications 1 (9): 957-972.
doi:10.1002/hep4.1084. http://dx.doi.org/10.1002/hep4.1084.
Published Version doi:10.1002/hep4.1084
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:35014855
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
The Ectonucleotidase ENTPD1/CD39
Limits Biliary Injury and Fibrosis in
Mouse Models of Sclerosing Cholangitis
Zhen-Wei Peng,1,2* Sonja Rothweiler,2* Guangyan Wei,2 Naoki Ikenaga,2 Susan B. Liu,2 Deanna Y. Sverdlov,2 Kahini A. Vaid,2
Maria Serena Longhi ,2 Ming Kuang,1 Simon C. Robson,2** and Yury V. Popov 2**
The pathogenesis of primary sclerosing cholangitis (PSC) and the mechanistic link to inﬂammatory bowel disease remain ill-
deﬁned. Ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1)/clusters of differentiation (CD) 39, the dominant
purinergic ecto-enzyme, modulates intestinal inﬂammation. Here, we have explored the role of CD39 in biliary injury and
ﬁbrosis. The impact of CD39 deletion on disease severity was studied in multidrug resistance protein 2 (Mdr2)–/– and 3,5-
diethoxycarbonyl-1,4-dihydrocollidine mouse models of sclerosing cholangitis and biliary ﬁbrosis. Antibody-mediated CD81
T-cell depletion, selective gut decontamination, experimental colitis, and administration of stable adenosine triphosphate
(ATP) agonist were performed. Retinoic acid-induced gut imprinting on T cells was studied in vitro. Over half of Mdr2–/–;
CD39–/– double mutants, expected by Mendelian genetics, died in utero. Compared to Mdr2–/–;CD391/1, surviving
Mdr2–/–;CD39–/– mice demonstrated exacerbated liver injury, ﬁbrosis, and ductular reaction. CD39 deﬁciency led to a
selective increase in hepatic CD81 T cells and integrin a4b7, a T-cell gut-tropism receptor. CD81 cell depletion in
Mdr2–/–;CD39–/– mice diminished hepatobiliary injury and ﬁbrosis. Treatment with antibiotics attenuated, whereas dextran
sulfate sodium-induced colitis exacerbated, liver ﬁbrosis in Mdr2–/– mice. Colonic administration of ab-ATP into CD39-
sufﬁcient Mdr2–/– mice triggered hepatic CD81 cell inﬂux and recapitulated the severe phenotype observed in Mdr2–/–;
CD39–/– mice. In vitro, addition of ATP promoted the retinoic acid-induced imprinting of gut-homing integrin a4b7 on
naive CD81 cells. CD39 expression was relatively low in human normal or PSC livers but abundantly present on immune
cells of the colon and further up-regulated in samples of patients with inﬂammatory bowel disease. Conclusion: CD39 deletion
promotes biliary injury and ﬁbrosis through gut-imprinted CD81 T cells. Pharmacological modulation of purinergic signal-
ing may represent a promising approach for the treatment of PSC. (Hepatology Communications 2017;1:957–972)
Introduction
Primary sclerosing cholangitis (PSC) is a progres-sive cholestatic liver disease characterized byinﬂammation and ﬁbrosis of the intrahepatic and
extrahepatic bile ducts and leads to biliary cirrhosis and
end-stage liver disease. Patients with PSC are at increased
risk of developing cholangiocarcinoma, hepatocellular car-
cinoma, and colorectal cancer.(1) Effective treatments are
lacking, and liver transplantation remains the only thera-
peutic option for patients with end-stage PSC.(2)
While the etiology of PSC remains unknown, the
associations with inﬂammatory bowel disease (IBD)
are well established, with at least 70% of patients with
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PSC also suffering from IBD.(3) After transplantation,
PSC recurrence in liver graft can be high (up to 30%)
and reduced in patients who have undergone colec-
tomy before or during liver transplantation. However,
recurrent PSC is not completely prevented, putatively
due to the persistence of gut-primed long-lived mem-
ory T cells.(4) Based on these and other observations,
PSC is hypothesized by some to be triggered by colitis,
where gut-primed effector T cells aberrantly home to
the liver and trigger portal inﬂammation in PSC.(5)
While genome-wide association studies suggest that
IBD in patients with PSC is genetically distinct from
non-PSC-associated IBD,(6) it is likely that targeting
or modulation of intestinal inﬂammation may result in
the alleviation of liver disease in PSC.
Gut tropism of clusters of differentiation (CD)81
T cells is determined by the expression of integrin
a4b7 and chemokine (C-C motif) receptor 9 (CCR9),
which are imprinted in mesenteric lymph nodes and
Peyer’s patches in a retinoic acid (RA)-dependent
manner.(7,8) Aberrant hepatic expression of gut-
homing signals mucosal vascular addressin cell adhe-
sion molecule 1 (MAdCAM-1) and chemokine (C-C
motif) ligand 25 (CCL25) have been reported in
patients with PSC, and these allow recruitment of
intestinal T cells to the liver.(9) However, the extent by
which the (auto)immune system contributes to PSC
pathogenesis remains obscure and controversial.
Interestingly, PSC is associated with several autoim-
munity susceptibility loci and is strongly linked to
human leukocyte antigen(10) but does not respond to
steroids or immunosuppressive therapies.(11) On the
other hand, recent data link the immunomodulatory
effects of vitamin D supplementation to promising
clinical responses in patients with PSC.(12)
The purinergic system is a critical modulator of
immune responses given the differential properties of
proinﬂammatory adenosine triphosphate (ATP) and
its immunosuppressive derivatives, such as adenosine.
Extracellular ATP is released during inﬂammation and
is rapidly hydrolyzed to adenosine diphosphate, adeno-
sine monophosphate (AMP), and adenosine by an
ecto-enzymatic cascade involving CD39 and CD73.
The ectonucleotidase CD39/ENTPD1 is expressed on
immune cells: T cells, B cells, monocytes/macro-
phages, natural killer cells, and dendritic cells. More
recent data indicate that CD39 expression on TH17
cells dictates immunomodulatory effects and immune
plasticity in inﬂammatory disease.(13,14)
In PSC, impaired immunoregulatory T-cell func-
tion(15) as well as increased TH17 responses
(16) support
a mechanism mediated by T cells. Whether CD39 is
involved in the regulation of underlying immune-
mediated responses leading to tissue injury in PSC is
not known. Here, we studied the potential contribution
of purinergic signaling in driving liver injury and ﬁbrosis
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in mouse models of PSC, using genetic and pharmaco-
logic approaches.
Materials and Methods
ANIMALS
All animals were housed in a speciﬁc-pathogen-free
facility at Beth Israel Deaconess Medical Center
(BIDMC; Boston, MA) with a 12-hour light–dark
cycle and were permitted ad libitum consumption of
water and a standard chow diet unless otherwise stated.
All animal procedures were approved by the Institu-
tional Animal Care and Use Committee at BIDMC
(protocols 004-2012 and 010-2015).
GENERATION OF CONGENIC
C57BL/6.MDR2–/– MOUSE
Friend virus B-type (FVB).multidrug resistance pro-
tein (Mdr2)–/– mice (FVB.129P2-Abcb4tm1Bor/J; Jack-
son Laboratory) were backcrossed at BIDMC onto a
C57Bl/6 background using an accelerated microsatellite
marker-assisted protocol (“speed congenics”). Brieﬂy,
backcrossing Mdr2–/– (FVB.129P2-Abcb4tm1Bor/J) on
the C57Bl/6J background was carried out by mating
mice heterozygous for the Mdr2 deletion with wild-type
(WT) C57Bl/6J mice obtained from Jackson Laboratory
(Bar Harbor, ME). A minimum of 19 male Mdr2
mutation carriers were produced in each generation, and
their genome screened using microsatellite marker
differences (simple sequence length polymorphisms)
at Jackson Laboratory (https://www.jax.org/jax-mice-
and-services/breeding-and-rederivation-services/speed-
congenic) for the percentage of C57Bl/6J background.
Individual carriers with the highest percentage of the
C57Bl/6J genome were selected for the next round of
breeding until the fully congenic state was reached at
generation N5 (99.9% of C57Bl/6J as assessed by a
complete genome scan). N5 heterozygotes were inter-
crossed to obtain fully congenic C57Bl/6J.Mdr2–/–
mice (herein referred to as Mdr2–/–) as founders of our
breeding colony.
CD39–/– mice on the C57Bl/6 background were
described,(17) and Mdr2–/–;CD39–/– double-mutant
mice (C57Bl/6 background) were generated by crossing
C57Bl/6J.Mdr2–/– with C57Bl/6.CD39–/– mice to
obtain F1 double-heterozygous mutants and intercrossing
F1 mice to obtain F2 progeny (n 5 148). F2 progeny
were genotyped at weaning, and mice of both sexes were
phenotyped at age 8 weeks as described.(18) For further
studies and long-term outcomes, three Mdr2–/–
;CD39–/– mice (one male, two females) in the F2 gener-
ation were bred to establish a colony of double knockouts.
In vivo CD81 T-cell depletion was performed using
a single intraperitoneal dose of anti-CD8 antibody at 120
lg/mouse, as described,(19) in age-matched Mdr2–/–;
CD39–/– mice challenged with a low-dose cholic acid
(0.1% diet) feeding for 1 week. Efﬁcacy of depletion was
conﬁrmed by immunoﬂuorescence in CD8-depleted liv-
ers and ﬂuorescence-activated cell sorting analysis of sple-
nocytes 3 days after anti-CD8 antibody injection.
ATP agonist administration of stable ATP analogue
ab-ATP (1 mg/mouse/day; Tocris Bioscience) was
dispensed rectally into 5-week-old Mdr2–/– mice for 6
days to mimic the effects of gut ﬂora-derived ATP as
described.(20)
Naive CD81 T-cell isolation and in vitro gut
imprinting was performed as described.(7) Brieﬂy, naive
CD81 cells were puriﬁed from spleens and peripheral
lymph nodes from WT mice by red blood cell lysis fol-
lowed by negative immunomagnetic selection (Miltenyi
Biotec, Auburn, CA) using MACS LS columns (Milte-
nyi Biotec). T cells were cultured with CD3/CD28
beads in a 1:1 ratio either with dimethyl sulfoxide, with
50 nM RA (Sigma, St. Louis, MO) or with 50 nM RA
plus 250 lM ATP (Sigma). Surface expression of a4b7
and CCR9 were assessed after 3-5 days of culture.
HUMAN LIVER AND COLON
SAMPLES
Human colon samples were obtained from patients
with IBD (ulcerative colitis, n 5 7) undergoing colon
resection. Human explant liver samples were obtained
from patients with end-stage PSC (n 5 5) or primary
biliary cholangitis (PBC; n 5 4) undergoing ortho-
topic liver transplantation. Wedge biopsies of normal
human colon (n5 7) or livers (n5 2) served as normal
controls. All patients gave written informed consent,
and the study protocol was approved by the Ethics
Committee of the First Afﬁliated Hospital of Sun Yat-
sen University (Guangzhou, China). Samples were de-
identiﬁed before analysis for this study.
STATISTICAL ANALYSIS
Data were expressed as mean 6 SEM and analyzed
using GraphPad Prism version 5.0 (GraphPad Soft-
ware, San Diego, CA). Statistical comparisons between
two groups were performed using the Student t test. P
< 0.05 was considered signiﬁcant. Additional methods
can be found in Supporting Material.
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Results
CD39 DELETION AGGRAVATES
LIVER INJURY AND PERIBILIARY
FIBROSIS IN MOUSE MODELS
To determine the role of purinergic signaling in bili-
ary injury and ﬁbrosis, we crossed mice with global
CD39 deletion (CD39–/–) with Mdr2–/– mice that
spontaneously develop PSC-like biliary disease (see
Materials and Methods for details). The double-null
mutants (Mdr2–/–;CD39–/–) on a C57Bl/6 back-
ground experienced high rates of fetal wastage and
were not born at the expected Mendelian ratio; only
43% of the expected double mutants were born (4 out
of 9 expected from a total of 148 F2 pups). In surviving
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Mdr2–/–;CD39–/– mice, liver injury and biliary
ﬁbrosis were evaluated at the age of 8 weeks when
ﬁbrotic lesions are well developed in the Mdr2–/–
model(21) compared to the Mdr2–/–;CD391/1 and
Mdr2–/–;CD391/– littermates. Sirius Red staining
demonstrated substantially more advanced portal
ﬁbrosis with frequent bridging in Mdr2–/–
;CD39–/– mice compared to Mdr2–/–;CD391/1
mice (Fig. 1A). This was accompanied by a more
pronounced ductular reaction in Mdr2–/–;CD39–/–
mice, with a 2-fold increase in pan-cytokeratin-
positive ductal cell counts compared to their CD39-
sufﬁcient littermates (P 5 0.0034) (Fig. 1A,C).
Hepatic collagen content increases (above the
normal baseline levels of 230.9 6 28.91 lg/liver in
WT controls) were signiﬁcantly greater by 48%
in CD39-deﬁcient Mdr2–/– mice (652.8 6 50.87
lg/liver versus 515 6 21.48 lg/liver; P < 0.05,
analysis of variance) (Fig. 1B). Mdr2–/–;CD39–/–
mice had 2-fold elevated serum alanine aminotrans-
ferase (ALT) levels compared to the control
CD39-sufﬁcient littermates (P < 0.01), indicating
increased hepatocyte injury in the double-null mice
(Fig. 1D). While Mdr2–/– female mice demon-
strated slightly more severe liver disease, no sex dif-
ference was observed in Mdr2–/– mice with CD39
deﬁciency (not shown) compared to male littermates
(Fig. 1A-G).
These ﬁndings were accompanied by up-regulation
of proﬁbrogenic messenger RNAs (mRNAs), includ-
ing Col1a1 and transforming growth factor b2 (P <
0.05; Fig. 1E). Interestingly, deletion of a single
functional CD39 copy in Mdr2–/–;CD391/– mice
did not affect collagen deposition, serum ALT, or
gene expression.
The CD39 deletion-related increase in disease
severity persisted over the lifetime of Mdr2–/–
;CD39–/– mice. No mortality was observed in adult
mice of either genotype up to 1 year of age. At 12
months of age, Mdr2–/–;CD39–/– mice exhibited
more severe ﬁbrosis/cirrhosis than Mdr2–/– mice his-
tologically and biochemically, with signiﬁcantly greater
increases (by 67.7%) in collagen levels (P 5 0.0013, t
test) (Fig. 1F,G). Notably, a much more pronounced
panlobular perisinusoidal ﬁbrosis was observed histo-
logically throughout the liver parenchyma in aged
Mdr2–/–;CD39–/– mice, consistent with a cirrhosis-
like stage in this model.(18,22)
Importantly, CD39 deletion produced a similar
proﬁbrotic phenotype in a second mechanistically
different model of biliary injury and putative scleros-
ing cholangitis, as induced by 3 weeks of 3,5-dieth-
oxycarbonyl-1,4-dihydrocollidine feeding. Here,
CD39 deﬁciency resulted in more severe ﬁbrosis
histologically, with an almost 2-fold increase in
hepatic collagen accumulation (P 5 0.0009; Support-
ing Fig. S1).
LOSS OF CD39 LEADS TO CD81
T-CELL INFILTRATION IN THE
LIVER
Next, we characterized the impact of CD39 deﬁ-
ciency on immune cells in livers of Mdr2–/– and
Mdr2–/–;CD39–/– mice. Flow cytometry analysis of
intrahepatic lymphocytes showed a selective increase
in CD81 T cells from 20.7% 6 1.62% in Mdr2–/–
mice to 36.4% 6 3.2% in CD39 deﬁcient Mdr2–/–
mice (P 5 0.0143) (Fig. 2A). Quantitative reverse-
transcription polymerase chain reaction analysis also
conﬁrmed an increase in hepatic CD8 mRNA expres-
sion (P 5 0.037), while CD3 and CD4 mRNA levels
remained unchanged (Fig. 2B). Furthermore, loss of
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FIG. 1. CD39 gene disruption aggravates liver injury and ﬁbrosis in Mdr2–/– mice. Mdr2–/–;CD39–/– double-mutant mice were
generated as described in Materials and Methods, and pups of both sexes phenotyped at 8 weeks of age in comparison to their
Mdr2–/–;CD391/1 and Mdr2–/–;CD391/– littermates (males are shown). (A) Representative pictures of connective tissue (Sirius
Red, left and middle) and p-CK (right) staining demonstrate portal ﬁbrosis and pronounced ductular reaction in Mdr2–/– mice,
respectively, which is exacerbated in Mdr2–/–;CD39–/– mice. Magniﬁcation 350 (left and right panel) and 3200 (middle panel, por-
tal area). (B) Liver hydroxyproline content, (C) p-CK-positive ductal cell counts (quantiﬁed from 10 random portal HPF area/liver at
3200, n 5 3/bar; *P 5 0.0034, t test), and (D) serum ALT levels are signiﬁcantly increased in Mdr2–/–;CD39–/– compared to
Mdr2–/– mice. (E) CD39 deletion leads to an up-regulation of Col1a1 and Tgfb2 mRNA expression. qRT-PCR data are shown as
fold increase compared to age-matched WT controls. Data (B-E,G) are mean 6 SEM (n 5 3-6 mice/bar). *P < 0.05 compared to
Mdr2–/–;CD391/1 controls (ANOVA followed by Dunnett’s posttest). (F) Mdr2–/–;CD39–/– mice at 12 months old demonstrate
severe periductular scarring that extends into liver parenchyma (sinusoidal ﬁbrosis), while ﬁbrotic lesions in Mdr2–/– mice are con-
ferred to the periportal region (Sirius Red, 3200, portal area). (G) Total hepatic hydroxyproline content in Mdr2–/–;CD39–/– mice
(n 5 8) compared to Mdr2–/– mice (n 5 12) at the age of 12 months (**P 5 0.0013, t test). Abbreviations: ANOVA, analysis of
variance; het, heterozygous; HPF, high-power ﬁeld; ko, knockout; p-CK, pan-cytokeratine; qRT-PCR, quantitative reverse-
transcription polymerase chain reaction; Tgfb2, transforming growth factor b2; wt, wild type.
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CD39 resulted in elevated hepatic expression of the
gut-tropism T-cell marker integrin b7 (P 5 0.045),
while the other gut-homing marker CCR9 demon-
strated a trend (P 5 0.127, not signiﬁcant) toward
increased expression (Fig. 2C). Immunostaining of
Mdr2–/– livers revealed ectopic expression of the cor-
responding adhesion molecules for gut-primed lym-
phocytes MAdCAM1 (ligand for integrin a4b7) and
CCL25 (receptor for CCR9), with marked hepatic
immunopositivity for MAdCAM1 (and to a lesser
extent CCL25) irrespective of CD39 genotype (Fig.
2D). Of note, F4/80 staining revealed pronounced
macrophage inﬁltration within periportal ﬁbrotic
lesions in Mdr2–/– mice but no apparent differences
were observed due to CD39 ablation (Supporting
Fig. S2).
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FIG. 2. Loss of CD39 is associated with CD81 T-cell inﬁltration in the liver. (A) FACS analysis of liver-inﬁltrating lymphocytes
isolated from 8-week-old male mice. Representative dot plots of CD3-gated hepatic lymphocytes (average values shown) and mean 6
SEM for CD81 T-cell quantiﬁcation (gated on CD3) in Mdr2–/– (n 5 3) versus Mdr2–/–;CD39–/– (n 5 5). (B,C) qRT-PCR
analysis of T-cell subsets and T-cell-related tropism markers shown as fold relative to Mdr2–/–. (D) Immunohistochemical staining of
liver for MAdCAM-1 and CCL25. Values are presented as mean 6 SEM. *P < 0.05 for Mdr2–/– versus Mdr2–/–;CD39–/–
(t test). Abbreviations: FACS, ﬂuorescence-activated cell sorting; qRT-PCR, quantitative reverse-transcription polymerase chain reaction.
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CD81 T-CELL DEPLETION
AMELIORATED LIVER INJURY
AND FIBROGENESIS IN Mdr2–/–
MICE WITH CD39 DEFICIENCY
In order to determine whether increased CD81 T
cells are bystanders or functionally modulate severity of
sclerosing cholangitis in CD39–/– mice, we performed
CD8-selective cell depletion using anti-CD8 antibody
in Mdr2–/–;CD39–/– mice. In the liver, CD81 cells
were virtually undetectable by immunoﬂuorescence in
antibody-treated mice (Fig. 3A). Flow cytometry anal-
ysis of splenocytes 3 days after a single anti-CD8 anti-
body injection conﬁrmed highly selective and efﬁcient
(>98%) CD81 T-cell depletion, with no changes in
CD41 T cells (Fig. 3B). Mice with CD81 cell deple-
tion showed a trend to a decreased mean serum ALT
level (1152 6 84.93 U/L versus 1410 6 146.7 U/L; P
5 0.167, not signiﬁcant) and a signiﬁcant reduction in
alkaline phosphatase (ALP; 764 6 65.70 U/L versus
1076 6 109.4 U/L; P 5 0.04) (Fig. 3C). This was
accompanied by the following signiﬁcant changes in
ﬁbrosis-related hepatic gene expression: 2-fold increase
in collagenases matrix metalloproteinase (Mmp)8 and
Mmp13 and a corresponding decrease in endogenous
MMP inhibitor tissue inhibitor of metalloproteinase-1
(Timp1) (Fig. 3D). The observed “proﬁbrolytic” gene
expression signature has previously been associated
with a favorable ﬁbrosis outcome in long-term experi-
ments performed in Mdr2–/– mice.(22) Collectively,
these data suggest that liver-inﬁltrating CD81 T cells
directly contribute to increased liver injury and ﬁbro-
genesis in Mdr2–/–;CD39–/– mice.
INTESTINAL BACTERIA
PROMOTE SCLEROSING
CHOLANGITIS IN Mdr2–/– MICE
Because of the strong association of PSC with colitis
and the major role of gut ﬂora-derived purines in
immune cell homeostasis,(20) we assessed the role of
gut ﬂora in the regulation of liver disease severity in
Mdr2–/– mice. First, colitis was induced by 3% and
5% dextran sulfate sodium (DSS)-containing drinking
water for 7 days, and the effect on liver ﬁbrosis was
evaluated 7 days after DSS discontinuation. Adminis-
tration of 3% and 5% DSS resulted in clinically moder-
ate (mild diarrhea) and severe (weight loss, diarrhea,
blood in stool) colitis, respectively, which was con-
ﬁrmed histologically (Fig. 4A).
DSS-induced colitis exacerbated sclerosing chol-
angitis with increased ductular reaction and bridging
ﬁbrosis (Fig. 4A). Consistent with histology, hepatic
collagen levels signiﬁcantly increased in a dose-
dependent manner in response to experimental coli-
tis, with up to 60% hydroxyproline increase (Fig. 4B)
and 2-fold to 3-fold increases in proﬁbrogenic tran-
scripts Col1a1 and transforming growth factor b2
(Fig. 4C).
Gut microﬂora is considered critical for the
development of DSS-induced colitis by triggering
inﬂammatory immune responses.(23) We further
interrogated the contribution of commensal bacteria
to liver ﬁbrosis in Mdr2–/– mice using selective gut
decontamination with an antibiotic cocktail to sup-
press Gram-negative bacteria (neomycin 1 poly-
mixin B) during active disease progression (4-
8 weeks of age) (Fig. 4D). Antibiotic-treated mice
demonstrated a signiﬁcant reduction of hepatic col-
lagen deposition histologically and biochemically
(Fig. 4E,F). These results suggest that intestinal
microbiota (and intestinal inﬂammation) signiﬁ-
cantly contribute to liver disease pathogenesis in our
system, recapitulating the gut–liver axis in the path-
ogenesis of PSC.
COLONIC ATP ADMINISTRATION
RECAPITULATES THE
PHENOTYPE OF EXACERBATED
SCLEROSING CHOLANGITIS DUE
TO LOSS OF CD39
CD39 controls the rate-limiting step (proinﬂamma-
tory) extracellular ATP conversion to AMP resulting
in the generation of (anti-inﬂammatory) adenosine.
Thus, the effects we observed following the loss of
CD39 in Mdr2–/– mice can be due to either increased
extracellular ATP signaling or the result of lower aden-
osine generation. We hypothesized that exacerbation
of the sclerosing cholangitis-type lesions in double-
null mice is the consequence of intestinal immune cell
activation through luminal ATP derived from either
gut bacteria or epithelial cells. To test this, Mdr2–/–
mice were rectally administered the stable ATP ana-
logue ab-ATP (1 mg/mouse) for 6 days to mimic the
effects of increased luminal ATP levels on CD39
deﬁciency.
In ab-ATP-treated Mdr2–/– mice, immunostain-
ing revealed accumulation of CD81 T cells in portal
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areas in close proximity to pan-cytokeratine-positive
biliary epithelium, with a >2-fold increase in hepatic
CD81 T-cell counts (10.32 6 0.38 versus 3.85 6
0.30 cells/high-power ﬁeld) and elevated CD8
mRNA when compared to vehicle controls (Fig.
5A,B). Furthermore, colonic ATP administration
resulted in signiﬁcantly elevated serum ALT (P 5
0.001) and ALP (P 5 0.018) levels (Fig. 5C). A
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FIG. 3. CD81 T-cell depletion ameliorates liver injury and has beneﬁcial effects on ﬁbrosis-related gene expression. (A) Immunoﬂuores-
cent staining of CD81 (red) and bile ducts visualized by pan-CK (green) in liver sections from male Mdr2–/–;CD39–/– mice 3 days after
administration of anti-CD8 monoclonal antibody or the respective isotype control (original magniﬁcation, 3200). (B) Flow cytometry
analysis of CD8 expression in splenocytes isolated from Mdr2–/–;CD39–/– mice treated for 3 days with anti-CD8 or isotype control.
Cells were gated on CD31 subsets. (C) CD81 T-cell depletion resulted in a signiﬁcant decrease in serum ALT and ALP. (D) CD81
T-cell depletion led to a proﬁbrolytic shift in gene expression with signiﬁcantly reduced TIMP-1 expression and increased MMP-8 and
MMP-13 expression. Data are mean 6 SEM (n 5 3-5 mice/bar). *P < 0.05 compared to isotype-treated control mice (t test). Abbrevia-
tions: CK, cytokeratine; IgG, immunoglobulin G; Tgfb2, transforming growth factor b2; TIMP-1, tissue inhibitor of metalloproteinase 1.
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FIG. 4. Intestinal bacteria promote sclerosing cholangitis in Mdr2–/– mice. (A) Experimental design of experimental colitis model in
6-week-old male FVB.Mdr2–/– mice. After 7 days of DSS administration, colitis was assessed, the DSS-supplemented water was
replaced by normal drinking water, and livers assessed 7 days later. Hematoxylin and eosin staining of colons (3200) and Sirius
Red staining of liver specimens from Mdr2–/– mice receiving drinking water (left), 3% DSS (middle), or 5% DSS (right) for 7 days.
Magniﬁcation 350 (middle panel) and 3200 (lower panel, portal area). (B) Hydroxyproline content in livers from control and DSS-
treated Mdr2–/– mice. (C) Hepatic expression of Col1a1 and Tgfb2. (D) Schematic outline for the antibiotic treatment in male
Mdr2–/– mice. (E) Hepatic hydroxyproline content and (F) representative connective tissue stain (Sirius Red, 350) in livers from
8-week-old Mdr2–/– mice after 4 weeks of antibiotic treatment with polymyxin B (100 mg/kg) 1 neomycin (220 mg/kg). Data are
shown as mean 6 SEM (n 5 4-5 mice/bar). *P < 0.05 compared to age-matched Mdr2–/– controls (analysis of variance followed by
Dunnett’s posttest). Abbreviations: DSS, dextran sulfate sodium; FVB, Friend virus B-type; Tgfb2, transforming growth factor b2.
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trend toward increased proﬁbrogenic genes (Fig. 5D)
and hepatic collagen deposition in animals treated
with ab-ATP was also observed (564.0 6 44.38 lg
versus 488.3 6 16.48 lg of hydroxyproline/liver;
P 5 0.131; data not shown), but these changes
did not reach statistical signiﬁcance, presumably
due to the relatively short (6 days) duration of this
experiment. Thus, colonic ATP administration in
Mdr2–/– mice mostly recapitulates the central
features of exacerbated sclerosing cholangitis pheno-
type due to CD39 deﬁciency in Mdr2–/–;CD39–/–
mice.
EXTRACELLULAR ATP
PROMOTES RA-DEPENDENT
IMPRINTING OF GUT-HOMING
RECEPTOR a4b7 ON NAIVE CD81
T CELLS
Aberrant homing of gut-speciﬁc lymphocytes to the
liver has been reported in patients with PSC(24,25) and
is consistent with increased CD81 T-cell and gut-
tropism T-cell markers in the livers of Mdr2–/–;
CD39–/– mice. Only gut-associated dendritic cells in
mesenteric lymph nodes or Peyer’s patches express the
                                                                                                                                      
FIG. 5. Colonic ATP administration to Mdr2–/– mice recapitulates the liver phenotype of Mdr2–/–;CD39–/– mice. Stable ATP ago-
nist (ab-ATP, 1 mg/kg/day) or vehicle (RPMI medium) was rectally administered into 5-week-old male Mdr2–/– mice daily for 6 days.
(A) Double immunoﬂuorescence for CD81 (red) and biliary marker p-CK (green) showed remarkable CD81 T-cell (arrowheads) inﬁl-
tration in portal areas in Mdr2–/– mice challenged with ab-ATP (original magniﬁcation, 3200). (B) CD81 T cells were quantiﬁed by
counting 10 randomly selected high-power ﬁelds and by measuring hepatic CD8 mRNA expression. (C) Elevation of serum ALT and
ALP in mice treated with ab-ATP. (D) mRNA expression of Col1a1, Tgfb2, as well as the gut-homing markers Itgb7, Ccr9 (n.s.).
Data are mean 6 SEM (n 5 3 mice/bar). *P < 0.05 compared to vehicle-treated Mdr2–/– (t test). Abbreviations: HPF, high-power
ﬁeld; Itgb7, integrin b7; n.s., not signiﬁcant; p-CK, pan-cytokeratine; RPMI, Roswell Park Memorial Institute; Tgfb2, transforming
growth factor b2.
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retinal dehydrogenase required to produce RA, which
is necessary for the imprinting of gut speciﬁcity on
lymphocytes.(8) High expression of CD39 by immuno-
ﬂuorescence was found in the intestine of Mdr2–/–
mice where it was abundantly present in nonepithelial
cells of the villi and Peyer’s patches. Indeed, a signiﬁ-
cant subset of CD39 cells within Peyer’s patches co-
expressed dendritic cell marker CD11c (Fig. 6A).
We hypothesized that CD39 on dendritic cells
may regulate imprinting of gut tropism on CD8
T cells. To test this, naive CD81 T cells were “gut
imprinted” with CD3/CD28 beads in the presence of
50 nM RA in vitro and analyzed by ﬂow cytometry.
By day 4, CCR9 was expressed on all CD81 T cells
(99.6%, data not shown) whereas only 71.11% of the
CD81 T cells were a4b7 positive (Fig. 6B). If cells
were activated in the presence of RA 1 ATP, the
expression of a4b7 was further enhanced to 91.8%
(Fig. 6B) while addition of adenosine had the
opposite effect (data not shown). RA-dependent
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FIG. 6. Extracellular ATP promotes RA-dependent imprinting of gut-homing receptor a4b7 on naive CD81 T cells. (A) Frozen
tissue sections of intestine from male Mdr2–/– mice were double stained for CD39 (green) and CD11c (red) using DAPI for nuclei
visualization. Photographs in the upper panel (magniﬁcation 3200) show CD39-positive cells in the mucosa, villi, and Peyer’s patch.
CD11c-positive cells were detected in villi and the Peyer’s patch. CD11c cells expressing CD39 were found in the Peyer’s patch and
in the villi. The lower panel at a higher magniﬁcation (3400) clearly demonstrates that a subset of DC is CD11c/CD39 double posi-
tive. (B) Flow cytometry analysis of a4b7 expression in naive CD81 T cells cultured for 4 days with CD3/CD28 beads in the pres-
ence of DMSO, 50 nM RA, or 50 nM RA 1 250 lM ATP. Representative dot plots of CD451 gated cells are shown with
numbers indicating the percentage of cells positive for CD8 and a4b7; in parentheses is the mean ﬂuorescence intensity for a4b7 in
CD81 cells. Results are shown from three different experiments (n 5 9). Bar graph: a4b7 expression (MFI) in CD451/CD81 cells
stimulated with 50 nM RA with or without ATP was normalized to DMSO-stimulated cells (mean 6 SD). ***P < 0.001. Abbrevia-
tions: DAPI, 40,6-diamidino-2-phenylindole; DC, dendritic cell; DMSO, dimethyl sulfoxide; MFI, mean ﬂuorescence intensity; PP,
Peyer’s patch.
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gut-tropism imprinting in CD8 T cells isolated from
CD39–/– mice was not impaired compared to WT
mice (data not shown).
CD39 IS EXPRESSED BY IMMUNE
CELLS IN HUMAN COLON AND IS
FURTHER UP-REGULATED IN IBD
To survey CD39 expression in human colon, immu-
nostaining was performed in diagnostic biopsies from
healthy patients and patients with IBD. We observed
abundant CD39 expression by immune and endothe-
lial cells in control colon biopsies. In intestinal tissue
from patients with IBD, CD39 expression was
increased in terms of extent and intensity (Fig. 7A).
Immunohistochemical staining of CD39 in colon
biopsies showed a signiﬁcantly enhanced immunoreac-
tivity in IBD colon compared to control tissue samples
(2.9 versus 1.4; P 5 0.0036) (Fig. 7B). We investi-
gated the expression of CD39 in healthy livers and
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FIG. 7. Survey of CD39 expression in healthy and diseased human liver and colon. Formalin-ﬁxed intestinal tissue sections from
patients with IBD and healthy controls were immunohistochemically stained for CD39. (A) Representative images showing CD39
IHC scores 1-4 based on intensity and area of CD39 expression in human colon tissue. (B) Semiquantitative assessment of CD39
immunoreactivity in healthy and diseased intestinal tissue samples (mean 6 SD). **P < 0.05. (C) CD39 immunohistochemistry in
formalin-ﬁxed liver sections from PSC, PBC, and healthy livers. Representative pictures show examples for CD39 expression scored
as grades 1, 2, and 3. (D) Dot plot showing semiquantitatively assessed CD39 expression as overall expression in the liver (left) and as
sinusoidal CD39 expression (right). Each dot represents an individual specimen score. Abbreviation: IHC, immunohistochemistry.
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contrasted this in PSC and PBC livers. CD39 expres-
sion was detected on sinusoidal endothelial and
macrophage-like septal cells and did not differ signiﬁ-
cantly between healthy and diseased (PSC, PBC) livers
when assessed semiquantitatively (Fig. 7C,D). In gen-
eral, CD39 immunoreactivity in liver tissues was nota-
bly lower than in colon samples.
Discussion
By genetically deleting CD39, we provide evidence
that purinergic signaling regulates biliary injury and
ﬁbrosis in a murine PSC-like model of sclerosing chol-
angitis induced by Mdr2 deﬁciency. Worsening of liver
histopathology in CD39-deﬁcient Mdr2–/– mice
appears to be driven by extracellular ATP-dependent
hepatic inﬂux of CD8 T cells. In human samples,
CD39 expression is relatively low in normal and PSC
livers but is abundantly present on intestinal immune
cells in healthy colon and is further up-regulated in
IBD. In vitro, extracellular ATP promoted RA-
dependent gut-tropism imprinting on naive CD81 T
cells, a lymphocyte population known to contribute to
liver injury in PSC.
The strong clinical association of PSC with IBD
and the shared genetic susceptibility loci provide the
rationale that PSC and IBD have common underlying
pathophysiologic mechanisms. In both cases, the pre-
cise etiology remains unknown. In recent years, the gut
microbiome has been increasingly recognized as a criti-
cal factor in numerous immune-mediated diseases,
including IBD and PSC.(26) It is now generally
accepted that microbial dysbiosis is one of the key play-
ers in the inﬂammatory process in IBD.(27,28)
Using experimental colitis and selective gut decon-
tamination in the PSC-like Mdr2–/– mouse model,
we demonstrated that intestinal microbes contribute,
at least in part, to driving the liver injury and ﬁbrosis in
our model. This is in line with results of a recent, ran-
domized, double-blind study demonstrating signiﬁcant
improvements in serum ALP levels in patients with
PSC after 12 weeks treatment with vancomycin.(29)
However, another recent study reported paradoxical
worsening of cholangitis in germ-free Mdr2–/– mice
on a Friend virus B-type background, arguing for a
protective role of the gut microbiota.(30) This is in
direct contradiction to our data derived from speciﬁc-
pathogen-free Mdr2–/– mice, which clearly show
improvement in their liver disease with antibiotic-
mediated gut decontamination (and worsening on
induction of experimental colitis). The discrepancy is
difﬁcult to explain, but the profound differences in
immune system development in mice kept under
germ-free conditions may be a major confounder.(31) It
is clear that further studies are required to decipher
harmful versus protective effects of microbial ﬂora in
the pathogenesis of PSC.
The role of purinergic signaling in chronic liver dis-
ease remains unclear in that both ATP and adenosine
may promote liver ﬁbrosis. For example, adenosine
A2A receptor-deﬁcient mice are protected from CCl4–
or thioacetamide-induced ﬁbrosis. Similar effects were
observed in WT animals treated with adenosine recep-
tor antagonists.(32) Moreover, it has been shown that
adenosine generated by CD73 plays a critical role in
the development of hepatotoxin-induced ﬁbrosis.(33)
While these two studies imply that adenosine is proﬁ-
brogenic, Dranoff and colleagues(34) recently examined
the effects of ATP signaling and showed that blocking
of purinergic receptors with a synthetic P2 receptor
inhibitor attenuates CCl4-induced liver ﬁbrosis. Given
that CD39 impacts P2-mediated nucleotide signaling
through ATP degradation and generates AMP, a pre-
cursor for adenosine generation, it was uncertain which
pathway would be dominant in regulating sclerosing
cholangitis in our system.
Compared to Mdr2–/– mice, Mdr2–/–;CD39–/–
mice exhibited a worsened PSC phenotype with more
severe liver injury and ﬁbrosis and an increase in liver-
inﬁltrating CD81 T cells (Figs. 1 and 2). Administra-
tion of the stable ATP analogue ab-ATP into CD39-
sufﬁcient Mdr2–/– mice recapitulated the phenotype
observed with CD39 loss. These results suggest that
excess extracellular ATP rather than diminished aden-
osine is responsible for hepatic inﬂux of CD81 T cells
and worsened disease phenotype in Mdr2–/– due to
the loss of CD39. Selective CD81 cell depletion in
Mdr2–/–;CD39–/– further indicates that sequelae of
CD39 deﬁciency are primarily CD81 T cell mediated.
Interestingly, exogenous ATP directly promoted
RA-induced gut-tropism imprinting on naive CD81
T cells in vitro, providing a possible mechanistic expla-
nation for aberrant liver homing of gut-primed CD81
T cells observed in human PSC.(5,25)
Although the exact pathogenesis of PSC remains
elusive, there is a growing body of evidence that dysre-
gulated immune responses represent a critical mecha-
nism in PSC. Genome-wide association studies have
identiﬁed numerous immune-related susceptibility loci
for PSC in the human leukocyte antigen, macrophage
stimulating 1 gene, interleukin-2 (IL-2), and its
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receptor IL-2RA.(35) Several immune-mediated dis-
eases share some of the genetic risk factors, demon-
strating an immunologic component to be involved in
PSC development. Immunohistochemical studies
demonstrated a mixed inﬂammatory cell inﬁltrate pre-
dominantly consisting of T cells, natural killer cells,
and macrophages.(36-38) Several studies suggested that
T cells are the major inﬁltrating cells in PSC; however,
conﬂicting ﬁndings have been reported on the CD41
or CD81 T cells being the prevalent subset.(12,37,39)
In our study, we showed that the hepatic lymphocytic
inﬁltrate is due to increased recruitment of CD81
T cells that drive worsened liver disease in CD39-
deﬁcient Mdr2–/– mice. Remarkably, immunosup-
pressive therapy is not effective in PSC despite it
having several features of an immune-mediated dis-
ease.(40) On the other hand, immunomodulation
approaches (such as vitamin D supplementation) have
shown beneﬁcial results and may hold promise for
PSC.(12)
Our Mdr2–/–;CD39–/– mice showed an increased
number of CD81 T cells in the liver compared to
Mdr2–/– together with an up-regulation of the gut-
homing markers integrin a4b7 in the liver. MAdCAM-
1 and CCL25, the respective binding partners of a4b7
and CCR9 that mediate lymphocyte gut homing, were
also both expressed in livers from Mdr2–/– and
Mdr2–/–;CD39–/– mice, generally consistent with aber-
rant homing of T cells to the liver in human PSC.(9,41)
While none of these mice presented signs of overt colitis,
unlike the majority of patients with PSC, it is conceiv-
able that ATP-dependent T-cell activation(20) in the
intestine, which is a major site of T-cell differentia-
tion,(42) may promote distant T-cell-mediated injury as
observed in PSC or in Mdr2–/– mice.
ATP limits lymphocyte motility during antigen rec-
ognition and thereby potentiates lymphocyte activa-
tion.(43) Bacteria-derived ATP has been identiﬁed as a
critical driver of intestinal TH17 cell generation by
activating CD11c1 lamina propria cells to produce IL-
6 and IL-23 and thereby promoting TH17 differentia-
tion.(20) In our study, we showed a worsened liver phe-
notype accompanied by increased CD81 T-cell inﬂux
after rectal ATP administration. Moreover, we dem-
onstrated for the ﬁrst time that extracellular ATP
directly impacts imprinting of gut speciﬁcity by RA.
This observation supports the concept that ATP sig-
naling is involved in T-cell activation and gut-liver
trafﬁcking, thus promoting the progression of scleros-
ing cholangitis. This concept is further supported by
two sets of experiments that show 1) either CD39
deletion or rectal ATP administration led to an
increase in CD81 T cells and worsened biliary injury
and ﬁbrosis in Mdr2–/– mice and 2) conversely,
CD81 depletion attenuate the sclerosing cholangitis
in Mdr2–/–;CD39–/– mice. Both approaches support
our hypothesis that purinergic mechanisms control
CD81 T-cell responses and modulate ﬁbrosis pro-
gression in PSC. Based on our results, we propose the
novel concept that extracellular ATP in the lumen,
under control of CD39, promotes activation and gut-
liver trafﬁcking of CD81 effector T cells, thereby
driving progression of sclerosing cholangitis (summa-
rized in Fig. 8). Furthermore, we developed and char-
acterized robust experimental tools that will allow
further dissecting and interrogating this purinergic
pathway pharmacologically.
In summary, our ﬁndings demonstrate a previously
unrecognized role of purinergic signaling in regulating
biliary injury and ﬁbrosis. We showed that gut ﬂora
promote progression of cholangitis and that manipula-
tion of purinergic pathways either through CD39 dele-
tion or by boosting exogenous ATP levels in the colon
leads to an inﬂux of CD81 T cells to the liver and
aggravates liver injury and ﬁbrosis in animal models.
Pharmacological modulation of the purinergic system
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FIG. 8. Scheme of putative purinergic pathway regulating the
pathophysiologic gut–liver axis in PSC. Luminal ATP (released
from intestinal bacteria or injured mucosal cells) activates gut
DC/CD81 T cells as regulated by the cellular ectonucleotidase
CD39. CD81 T cells, once activated in the gut, trafﬁc to the
liver. In the liver, CD81 T cells (by effector functions) target
biliary epithelia, promoting cholangitis and periductular ﬁbrosis.
Abbreviation: DC, dendritic cell.
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may represent a promising new approach for the treat-
ment of PSC.
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